Eribulin Struktur

Eribulin

Bezeichnung:Eribulin

CAS-Nr253128-41-5

Englisch Name:Eribulin

CBNumberCB22546700

SummenformelC40H59NO11

Molgewicht729.9

MOL-Datei253128-41-5.mol

Eribulin physikalisch-chemischer Eigenschaften

Dichte	1.29±0.1 g/cm3(Predicted)
storage temp.	Store at -20°C
Löslichkeit	Soluble in DMSO
Aggregatzustand	Powder
pka	12.56±0.35(Predicted)
InChIKey	UFNVPOGXISZXJD-JBQZKEIOSA-N

Gefahreninformationscode (GHS)

Eribulin Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
The U.S. FDA approved eribulin mesylate (also referred to as E7389) in November 2010 for the treatment of metastatic breast cancer (MBC) for patients who previously received at least two chemotherapeutic regimens for late-stage disease. Eribulin is a synthetic analog of the marine natural product halichondrin B, which is isolated from the sea sponge Halichondria okadai. Eribulin retains most of the structural elements that constitute the right hand side of halichondrin B; structure–activity relationship (SAR) studies suggested that the antitumor activity of halichondrin B resides in that part of the molecule . Eribulin is a microtubule inhibitor that binds close to the vinca-binding site of tubulin. Unlike most tubulin inhibitors like taxanes, epothilones, and vinca alkaloids that inhibit microtubule dynamic instability by changing tubulin addition and loss parameters, eribulin’s effects on dynamic instability are novel in that eribulin inhibits the growth phase of microtubules without affecting the shortening phase by binding to microtubule plus ends.
Originator
Eisai (United States)
Verwenden
Eribulin is a anticancer drug and also is a fully synthetic macrocyclic ketone analogue of the marine natural product halichondrin B. It derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity.
Definition
ChEBI: Eribulin is a fully synthetic macrocyclic ketone analogue of marine sponge natural products. Inhibits growth phase of microtubules via tubulin-based antimitotic mechanism, which leads to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage It has a role as an antineoplastic agent and a microtubule-destabilising agent. It is a macrocycle, a polyether, a polycyclic ether, a cyclic ketone, a primary amino compound and a cyclic ketal. It is a conjugate base of an eribulin(1+).
Trademarks
Halaven
Clinical Use
Antineoplastic agent:
Treatment of metastatic breast cancer
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs Antipsychotics: avoid concomitant use with clozapine (increased risk of agranulocytosis).
Stoffwechsel
Minimal metabolism. Eribulin is eliminated primarily by biliary excretion. The transport protein involved in the excretion is presently unknown. Preclinical studies indicate that eribulin is transported by Pgp. However, it is unknown whether Pgp is contributing to the biliary excretion of eribulin.
Mode of action
Eribulin is a non-taxane, microtubule dynamics inhibitor that increases survival of patients with metastatic breast cancer. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.

Eribulin Upstream-Materialien And Downstream Produkte

Eribulin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

253128-41-5, Eribulin Verwandte Suche:

Send Inquriy